Renibus Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.renibus.com
Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Retrospective Observational Study of Patients Who Have Undergone Coronary Artery Bypass Graft (CABG) and/or Cardiac Valve Surgery
- Conditions
- Post-discharge Outcomes
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Renibus Therapeutics, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT07009340
- Locations
- 🇺🇸
Heart Center Research, LLC, Huntsville, Alabama, United States
🇺🇸Lutheran Medical Center, Fort Wayne, Indiana, United States
🇺🇸My Michigan Medical Center, Midland, Michigan, United States
An Evaluation of Patient Reported Outcomes and Clinical Outcomes
- Conditions
- Post-Operative Complications in Cardiac Surgery
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Renibus Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT06092970
- Locations
- 🇨🇦
Research Site, Québec, Quebec, Canada
🇺🇸New York Presbyterian-Queens, Flushing, New York, United States
Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery
- Conditions
- Post-Operative Complications in Cardiac Surgery
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Renibus Therapeutics, Inc.
- Target Recruit Count
- 454
- Registration Number
- NCT06021457
- Locations
- 🇨🇦
Research Site, Québec, Quebec, Canada
Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery
- Conditions
- AKI
- Interventions
- Drug: High Dose RBT-1Drug: PlaceboDrug: Low Dose RBT-1
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Renibus Therapeutics, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT04564833
- Locations
- 🇺🇸
Heart Center Research, LLC, Huntsville, Alabama, United States
🇺🇸Keck Hospital of USC, Los Angeles, California, United States
🇺🇸Santa Barbara Cottage Hospital, Santa Barbara, California, United States
A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)
- Conditions
- COVID-19
- Interventions
- Drug: RBT-9 (90 mg)
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Renibus Therapeutics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04364763
- Locations
- 🇺🇸
New Smyrna Beach, FL, New Smyrna Beach, Florida, United States
🇺🇸Berkley, MI, Berkley, Michigan, United States
🇺🇸El Paso, TX, El Paso, Texas, United States
- Prev
- 1
- 2
- Next